Compare KALU & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | TRVI |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2006 | 2019 |
| Metric | KALU | TRVI |
|---|---|---|
| Price | $149.33 | $12.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $168.25 | $28.18 |
| AVG Volume (30 Days) | 159.5K | ★ 1.8M |
| Earning Date | 10-21-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 135.89 | 31.91 |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $1,585,900,000.00 | N/A |
| Revenue This Year | $42.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.46 | $9.29 |
| 52 Week High | $199.89 | $20.22 |
| Indicator | KALU | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 20.25 |
| Support Level | $148.79 | $10.13 |
| Resistance Level | $150.00 | $13.55 |
| Average True Range (ATR) | 5.44 | 0.60 |
| MACD | 0.40 | -0.11 |
| Stochastic Oscillator | 49.45 | 18.82 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.